Pipeline & Proof of Concept

Our robust and growing pipeline has the potential to play a critically influential role in the practice of Gut Microbiome Medicine and create significant value for patients and shareholders.

CS Therapeutic Pipeline

Therapeutic area

Gastroenterology / Infectious Disease

Oncology

Indication

POC*

DISCOVERY

PRECLINICAL

Phase I

Phase II

Phase III

Surgical Site Infection / Anastomotic Leak

Inflammatory Bowel Disease

Sepsis

C. Diff. / C. Diff. Recurrence

CS-0003, Phase I in 2027

CS-0003, Preclinical POC underway

CS-0003

CS-0003

Colon Cancer Recurrence

Chemotherapy-related Toxicities and Infections

Radiation Toxicities

CS-0003

CS-0003, non-dilutive grant R&D

CS-0003

The study is in progress.

Highlighted Proof of Concept Publications Below:

Anastomotic Leak

SSI via Trojan Horse Mechanism

Sepsis

Colon Cancer Recurrence

Thought Leadership

Dr. Eugene Chang’s NIH-funded lab, the Chang Lab at the University of Chicago in collaboration with The University of Chicago Duchossois Family Institute produced the GB diagnostic technology platform.

GB: GI Discovery Platform

Therapeutic area

Gut Microbiome
Function

Use Cases

Potential Partners

Adult Gut Health (18+)

Surgical Site Infection / Anastomotic Leak Risk

IBD Patient Stratification

DFI, Mayo Clinic, UGH (Optum), Kroger

Internal development

J&J, AbbVie, Takeda, Merck, Pfizer, Eli Lilly

Unmet need and thought leadership: